TIBCO Software Inc., together with INTEGROMICS, a provider of software solutions for data management and data analysis in genomics, proteomics and drug discovery, announced a solution for genomics research that provides researchers and scientists with a direct, interactive, visual approach to data analysis that rapidly reveals insights and unexpected relationships in genomics data.
TIBCO SPOTFIRE AND INTEGROMICS ANNOUNCE GENOMICS DATA ANALYSIS SOLUTION TO RADICALLY SPEED DRUG RESEARCH AND DEVELOPMENT
Spotfire Platform Evolves with INTEGROMICS to Lead the Industry in Advancing Life Sciences Research, Discovery and Development
SOMERVILLE, Mass., – September 24, 2008 –TIBCO Software Inc. (NASDAQ: TIBX), together with INTEGROMICS, a provider of state-of-the-art software solutions for data management and data analysis in genomics, proteomics and drug discovery, today announced a solution for genomics research that provides researchers and scientists with a direct, interactive, visual approach to data analysis that rapidly reveals insights and unexpected relationships in genomics data.
Genomics technologies - used by pharmaceutical R&D departments to understand disease biology and drug response in order to develop new and better drugs -- are now used across the entire drug development process to better understand disease biology, mechanisms of drug action, mechanisms of toxicity, and individuals and their response to a drug. Genomics-based biomarkers are dramatically impacting drug development by providing more precise diagnoses of disease states and drug response in individual patients. The software used to analyze and explore genomic data had not kept pace with the advancing genomics research. Spotfire and INTEGROMICS, however, joined forces to address the needs of modern genomics research in areas including biomarker research, translational medicine, and systems biology by introducing INTEGROMICS Biomarker Discovery for TIBCO Spotfire®.
The scientific and workflow knowledge of INTEGROMICS, combined with the adaptability and ease of use of the TIBCO Spotfire platform, provide researchers with a powerful genomic data analysis environment. The new solution enables pharmaceutical, biotechnology, and academic research groups to quickly find and categorize complex patterns. With interactive analysis and high-impact visualization capabilities, researchers and scientists can examine the expression and annotation dimensions of their data and perform a variety of numerical analyses. Pharmaceutical companies can also use Spotfire® as a flexible analytics platform to allow them to combine and analyze new types of data in order to more quickly pursue their hypotheses and research strategies.
“Having developed microarray analytics for the last five years, we are confident that this combined solution will provide researchers with a powerful environment to accelerate discovery and provide accurate, up-to-date analytics from a single reliable source,” said Alberto Pasqual, vice president of R & D, INTEGROMICS. “With this set of tools, life science researchers can ask and answer new questions and create an advanced problem solving environment.”
“Genomics research typically involves measuring the activity of thousands of genes in many different treatments or conditions and combining that information with other information about the genes to uncover information about the biology of disease and treatment,” said Christian Marcazzo, senior director of Life Science Analytics for TIBCO Spotfire. “This solution helps researchers and scientists address one of the industry’s long standing challenges of creating knowledge from mass data by easily integrating multiple data sources and transforming data into an interactive decision-making asset.”
About INTEGROMICS
INTEGROMICS, S.L. provides IT solutions for Life Sciences (Genomics and Proteomics). In the post-genomic era, Integromics S.L. offers state-of-the-art products, services and training in two strategic areas: data management/integration and intelligent data analysis. The company has developed a network of collaborations both in industry and academia to provide complete technological solutions that will help our clients to achieve their goals. Integromics S.L., was founded in 2002 and is based in Granada, Spain, with offices in Madrid (Spain) and Philadelphia (USA). Integromics Inc. is a wholly owned subsidiary which was established in 2007. For more information, visit http://www.integromics.com/
About TIBCO
TIBCO Software Inc. is a leading provider of enterprise analytics software for next generation business intelligence. TIBCO Spotfire products offer a visual and interactive experience that helps professionals quickly discover new and actionable insights in information. Distinguished by its speed to insight and adaptability to specific business challenges, Spotfire rapidly reveals unseen threats and new opportunities, creating significant economic value. Spotfire customers include industry leaders among the Global 2000 that have deployed Spotfire analytics to gain an information advantage over their competitors. For more information, visit http://spotfire.tibco.com
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.